MCID: MYL031
MIFTS: 63

Myeloproliferative Neoplasm

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Myeloproliferative Neoplasm

MalaCards integrated aliases for Myeloproliferative Neoplasm:

Name: Myeloproliferative Neoplasm 12 55 6 15 38
Chronic Myeloproliferative Disease 12 55
Chronic Myeloproliferative Disorders 53
Chronic Myeloproliferative Disorder 73
Myeloproliferative Disease 73
Campomelic Dysplasia 73
Cmpd, U 12
Cmpd 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2226
ICD10 33 D47.1
NCIt 50 C4345
UMLS 73 C1292778

Summaries for Myeloproliferative Neoplasm

NIH Rare Diseases : 53 Chronic myeloproliferative disorders are a group of slow-growing blood cancers in which the bone marrow makes too many abnormal red blood cells, white blood cells, or platelets, which accumulate in the blood. The type of myeloproliferative disorder is based on whether too many red blood cells, white blood cells, or platelets are being made. Sometimes the body will make too many of more than one type of blood cell, but usually one type of blood cell is affected more than the others. There are 6 types of chronic myeloproliferative disorders: chronic myelogenous leukemia (CML), polycythemia vera, primary myelofibrosis (also called chronic idiopathic myelofibrosis), essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia. Chronic myeloproliferative disorders sometimes become acute leukemia, in which too many abnormal white blood cells are made.

MalaCards based summary : Myeloproliferative Neoplasm, also known as chronic myeloproliferative disease, is related to myelodysplastic myeloproliferative cancer and atypical chronic myeloid leukemia, and has symptoms including apnea and respiratory distress. An important gene associated with Myeloproliferative Neoplasm is H19 (H19, Imprinted Maternally Expressed Transcript
Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders.
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Busulfan and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A myeloid neoplasm that is characterized by a group of slow growing blood cancers in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood.

Wikipedia : 76 The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of... more...

Related Diseases for Myeloproliferative Neoplasm

Diseases related to Myeloproliferative Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic myeloproliferative cancer 32.8 JAK2 PTPN11 TET2
2 atypical chronic myeloid leukemia 31.9 ABL1 FGFR1 JAK2 PDGFRA
3 pdgfra-associated chronic eosinophilic leukemia 31.7 FIP1L1 PDGFRA
4 thrombocytosis 31.1 JAK2 MPL TET2
5 polycythemia 30.9 CALR JAK2 MPL TET2
6 myelofibrosis 30.9 CALR JAK2 KIT MPL SH2B3 STAT5B
7 refractory anemia 30.8 JAK2 MPL TET2
8 chronic myelomonocytic leukemia 30.6 JAK2 KIT PDGFRB TET2
9 budd-chiari syndrome 29.6 CALR FIP1L1 JAK2 PDGFRA
10 essential thrombocythemia 29.2 ABL1 BCR CALR JAK2 MPL SH2B3
11 polycythemia vera 28.7 ABL1 CALR H19 JAK2 KIT MPL
12 leukemia 28.6 ABL1 BCR JAK2 KIT MPL PTPN11
13 myelodysplastic syndrome 28.5 ABL1 JAK2 KIT MPL PDGFRB PTPN11
14 myeloid leukemia 28.4 ABL1 BCR JAK2 KIT PTPN11 TET2
15 lymphoblastic leukemia 28.3 ABL1 BCR JAK2 PTPN11
16 systemic mastocytosis 28.2 FGFR1 FIP1L1 JAK2 KIT PDGFRA PDGFRB
17 leukemia, chronic myeloid 27.9 ABL1 BCR FGFR1 H19 JAK2 KIT
18 leukemia, acute myeloid 26.5 ABL1 BCR JAK2 KIT MPL PTPN11
19 campomelic dysplasia 11.7
20 chromosome 14q32 duplication syndrome, 700-kb 11.2
21 myeloproliferative disorder, chronic, with eosinophilia 11.0
22 myeloproliferative syndrome, transient 11.0
23 chronic neutrophilic leukemia 11.0
24 cellular neurofibroma 10.6 ABL1 PDGFRB
25 thrombocythemia 1 10.5 CALR MPL SH2B3
26 reticular perineurioma 10.5 KIT PDGFRA
27 thrombosis 10.4
28 lymphoblastic leukemia, acute, with lymphomatous features 10.4 ABL1 FGFR1 JAK2
29 desmoid tumor 10.3 KIT PDGFRA PDGFRB
30 gastric leiomyosarcoma 10.3 KIT PDGFRA
31 philadelphia-negative chronic myeloid leukemia 10.3 ABL1 BCR
32 heart sarcoma 10.3 KIT PDGFRA PDGFRB
33 thrombocytopenia-absent radius syndrome 10.3 CALR FGFR1 JAK2 MPL
34 fibrosarcoma of bone 10.3 KIT PDGFRA PDGFRB
35 lymphoma 10.2
36 erythrocytosis, familial, 1 10.2 JAK2 SH2B3 STAT5B
37 sarcomatoid renal cell carcinoma 10.2 KIT PDGFRA
38 dermatofibrosarcoma protuberans 10.2 KIT PDGFRA PDGFRB
39 large granular lymphocyte leukemia 10.2 STAT3 STAT5B
40 leiomyosarcoma 10.2 KIT PDGFRA PDGFRB
41 conventional fibrosarcoma 10.2 KIT PDGFRA
42 undifferentiated pleomorphic sarcoma 10.1 KIT PDGFRA STAT3
43 lymphoblastic lymphoma 10.1
44 pdgfrb-associated chronic eosinophilic leukemia 10.1
45 thrombophilia due to thrombin defect 10.1
46 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.1 FGFR1 JAK2 PDGFRA PDGFRB
47 mast cell disease 10.1 KIT PDGFRA PDGFRB TET2
48 loeffler endocarditis 10.1 FIP1L1 PDGFRA
49 splenomegaly 10.0
50 endotheliitis 10.0

Graphical network of the top 20 diseases related to Myeloproliferative Neoplasm:



Diseases related to Myeloproliferative Neoplasm

Symptoms & Phenotypes for Myeloproliferative Neoplasm

UMLS symptoms related to Myeloproliferative Neoplasm:


apnea, respiratory distress

GenomeRNAi Phenotypes related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.68 PDGFRA
2 Decreased viability GR00221-A-1 9.68 ABL1 FGFR1 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 9.68 ABL1 FGFR1
4 Decreased viability GR00221-A-3 9.68 PDGFRB ABL1 PDGFRA
5 Decreased viability GR00221-A-4 9.68 PDGFRB PDGFRA
6 Decreased viability GR00301-A 9.68 KIT
7 Decreased viability GR00342-S-1 9.68 ABL1 PDGFRB
8 Decreased viability GR00342-S-2 9.68 ABL1
9 Decreased viability GR00342-S-3 9.68 ABL1
10 Decreased viability GR00402-S-2 9.68 ABL1 FGFR1 KIT PDGFRA PDGFRB
11 Decreased substrate adherent cell growth GR00193-A-1 9.43 KIT
12 Decreased substrate adherent cell growth GR00193-A-2 9.43 ABL1 KIT
13 Decreased substrate adherent cell growth GR00193-A-4 9.43 ABL1 FGFR1 KIT

MGI Mouse Phenotypes related to Myeloproliferative Neoplasm:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 TET2 ABL1 FGFR1 BCR JAK2 CALR
2 growth/size/body region MP:0005378 10.34 TET2 STAT5B CALR ABL1 FGFR1 BCR
3 hematopoietic system MP:0005397 10.32 TET2 ABL1 FGFR1 BCR JAK2 PDGFRA
4 immune system MP:0005387 10.29 TET2 ABL1 FGFR1 BCR JAK2 MPL
5 homeostasis/metabolism MP:0005376 10.27 STAT5B CALR ABL1 FGFR1 BCR JAK2
6 embryo MP:0005380 10.25 ABL1 FGFR1 JAK2 CALR MPL PDGFRA
7 cardiovascular system MP:0005385 10.24 TET2 CALR ABL1 FGFR1 PDGFRA KIT
8 endocrine/exocrine gland MP:0005379 10.24 TET2 STAT5B ABL1 FGFR1 JAK2 PDGFRA
9 mortality/aging MP:0010768 10.22 TET2 STAT5B CALR ABL1 FGFR1 BCR
10 digestive/alimentary MP:0005381 10.16 ABL1 FGFR1 BCR PDGFRA KIT STAT3
11 craniofacial MP:0005382 10.11 ABL1 FGFR1 PDGFRA KIT PDGFRB STAT3
12 integument MP:0010771 10.06 STAT5B FGFR1 JAK2 PDGFRA KIT PDGFRB
13 liver/biliary system MP:0005370 10.03 TET2 STAT5B ABL1 BCR JAK2 KIT
14 normal MP:0002873 10 TET2 ABL1 FGFR1 BCR JAK2 PDGFRA
15 muscle MP:0005369 9.97 CALR ABL1 FGFR1 PDGFRA KIT PDGFRB
16 neoplasm MP:0002006 9.8 TET2 JAK2 PDGFRA KIT STAT3 PTPN11
17 renal/urinary system MP:0005367 9.76 TET2 STAT5B FGFR1 BCR PDGFRA KIT
18 reproductive system MP:0005389 9.56 STAT5B FGFR1 JAK2 PDGFRA KIT PDGFRB
19 skeleton MP:0005390 9.23 ABL1 FGFR1 JAK2 PDGFRA KIT PDGFRB

Drugs & Therapeutics for Myeloproliferative Neoplasm

Drugs for Myeloproliferative Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 551)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-98-1 2478
2
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
3
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
4
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
5
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 127-07-1 3657
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
7
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
8
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
9 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 220127-57-1 123596
14 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
23 interferons Phase 4,Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
27 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
28 Tin Fluorides Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 tyrosine Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 147-94-4 6253
31
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
32
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
33
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
34
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
35
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
36
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
37
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 83-43-2 6741
38
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 50-24-8 5755
39
Iron Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7439-89-6 23925
40
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
41
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
42
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
43
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
44
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
45
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
46
Peginterferon alfa-2b Approved Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
47
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
48
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
49
Panobinostat Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 404950-80-7 6918837
50
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 1544)
# Name Status NCT ID Phase Drugs
1 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
2 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
3 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
4 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
5 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
6 Efficacy and Safety of Nilotinib in CML-CP Completed NCT03332511 Phase 4 Nilotinib
7 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
8 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
9 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
10 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
11 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
12 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
13 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
14 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
15 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
16 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
17 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
18 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
19 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
20 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
21 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
22 Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Recruiting NCT03232177 Phase 4 Anagre Cap.
23 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
24 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
25 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Active, not recruiting NCT01578213 Phase 4 Imatinib mesylate
26 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Not yet recruiting NCT02389920 Phase 4 Nilotinib
27 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
28 A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients Terminated NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
29 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
30 Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Terminated NCT02086487 Phase 4 Nilotinib 300 mg.
31 Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib Terminated NCT00461929 Phase 4
32 Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Withdrawn NCT01605981 Phase 4 AMN107
33 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
34 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
35 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
36 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
37 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
38 Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase Unknown status NCT00327262 Phase 3 Imatinib
39 Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Unknown status NCT00002869 Phase 3 cytarabine;hydroxyurea
40 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
41 Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00002771 Phase 3 busulfan;cytarabine;hydroxyurea;idarubicin
42 Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy Unknown status NCT00297570 Phase 3 Pegylated Interferon and Imatinib
43 Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib Unknown status NCT01400074 Phase 3 Nilotinib, Imatinib
44 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
45 Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Unknown status NCT00966810 Phase 2, Phase 3
46 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
47 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
48 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
49 Anagrelide Retard in Essential Thrombocythemia Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
50 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3

Search NIH Clinical Center for Myeloproliferative Neoplasm

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Myeloproliferative Neoplasm

Anatomical Context for Myeloproliferative Neoplasm

MalaCards organs/tissues related to Myeloproliferative Neoplasm:

41
Myeloid, Bone, Bone Marrow, T Cells, Testes, Kidney, Nk Cells

Publications for Myeloproliferative Neoplasm

Articles related to Myeloproliferative Neoplasm:

(show top 50) (show all 500)
# Title Authors Year
1
Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm. ( 29417354 )
2018
2
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. ( 29767839 )
2018
3
Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals. ( 29645296 )
2018
4
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review. ( 29656438 )
2018
5
Rapid development of myeloproliferative neoplasm in mice with <i>Ptpn11</i><sup> <i>D61Y</i> </sup> mutation and haploinsufficient for <i>Dnmt3a</i>. ( 29464054 )
2018
6
False-negative <i>CALR</i> mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action. ( 29463578 )
2018
7
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. ( 29459662 )
2018
8
<i>Sipa1</i> deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. ( 29514790 )
2018
9
A case of massive splenomegaly due to chronic myeloproliferative neoplasm. ( 29868160 )
2018
10
An evaluation of global coagulation assays in myeloproliferative neoplasm. ( 29538005 )
2018
11
Protracted Clonal Trajectory of a <i>JAK2</i> V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. ( 29854499 )
2018
12
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. ( 29465270 )
2018
13
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. ( 29148847 )
2018
14
Atypical chronic myeloid leukaemia - aA rare subtype of myelodysplastic/myeloproliferative neoplasm. ( 29692658 )
2018
15
Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy. ( 29516749 )
2018
16
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). ( 29067707 )
2018
17
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. ( 29355841 )
2018
18
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. ( 29051283 )
2018
19
A novel type of +2-base pair frameshift CALR mutation in a patient with myeloproliferative neoplasm. ( 29617043 )
2018
20
Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. ( 28057939 )
2017
21
<i>SETBP1</i> mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome. ( 29225884 )
2017
22
Molecular Investigation of a Suspected Myeloproliferative Neoplasm in Patients with Basophilia. ( 28571160 )
2017
23
The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients. ( 28497580 )
2017
24
JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism. ( 28401106 )
2017
25
A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. ( 28031530 )
2017
26
Irf8 regulates the progression of myeloproliferative neoplasm-like syndrome via Mertk signaling in zebrafish. ( 28626217 )
2017
27
Low-dose methotrexate in myeloproliferative neoplasm models. ( 28550185 )
2017
28
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. ( 28464892 )
2017
29
Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. ( 28668884 )
2017
30
JAK1 somatic mutation in a myeloproliferative neoplasm. ( 28550193 )
2017
31
Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. ( 27687869 )
2017
32
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. ( 28465517 )
2017
33
Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic veinA thrombosis. ( 29048104 )
2017
34
TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. ( 28218607 )
2017
35
JAK2V617F influences epigenomic changes in myeloproliferative neoplasms. ( 29066347 )
2017
36
Benefits and pitfalls of Peg-Interferon-I+2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis, a French Intergroup of Myeloproliferative neoplasms (FIM) study. ( 29217781 )
2017
37
Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. ( 27734130 )
2017
38
Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response. ( 29199511 )
2017
39
A t(1;9) translocation involving CSF3R as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm. ( 28935846 )
2017
40
Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms. ( 28422716 )
2017
41
Somatic mutations of calreticulin in myeloproliferative neoplasms. ( 28470469 )
2017
42
Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. ( 28731458 )
2017
43
Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status. ( 28314843 )
2017
44
Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. ( 28057739 )
2017
45
Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. ( 29090588 )
2017
46
The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. ( 28482711 )
2017
47
Lenalidomide-associated arterial thrombosis in a patient with JAK2 positive atypical myeloproliferative neoplasm. ( 28801515 )
2017
48
Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms. ( 27976991 )
2017
49
Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms. ( 28145534 )
2017
50
Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. ( 28062906 )
2017

Variations for Myeloproliferative Neoplasm

ClinVar genetic disease variations for Myeloproliferative Neoplasm:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MPL NM_005373.2(MPL): c.1514G> A (p.Ser505Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913614 GRCh37 Chromosome 1, 43814979: 43814979
2 MPL NM_005373.2(MPL): c.1514G> A (p.Ser505Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913614 GRCh38 Chromosome 1, 43349308: 43349308
3 MPL NM_005373.2(MPL): c.1513A> T (p.Ser505Cys) single nucleotide variant Likely pathogenic rs1057519752 GRCh37 Chromosome 1, 43814978: 43814978
4 MPL NM_005373.2(MPL): c.1513A> T (p.Ser505Cys) single nucleotide variant Likely pathogenic rs1057519752 GRCh38 Chromosome 1, 43349307: 43349307
5 JAK3 NM_000215.3(JAK3): c.1715C> T (p.Ala572Val) single nucleotide variant Likely pathogenic rs121913504 GRCh37 Chromosome 19, 17948009: 17948009
6 JAK3 NM_000215.3(JAK3): c.1715C> T (p.Ala572Val) single nucleotide variant Likely pathogenic rs121913504 GRCh38 Chromosome 19, 17837200: 17837200
7 KIT NM_000222.2(KIT): c.1675G> A (p.Val559Ile) single nucleotide variant Likely pathogenic rs121913520 GRCh38 Chromosome 4, 54727443: 54727443
8 KIT NM_000222.2(KIT): c.1675G> A (p.Val559Ile) single nucleotide variant Likely pathogenic rs121913520 GRCh37 Chromosome 4, 55593609: 55593609

Copy number variations for Myeloproliferative Neoplasm from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 33241 1 43803475 43820135 Mutation MPL Myeloproliferative neoplasm
2 44192 10 53300000 71300000 Loss Myeloproliferative neoplasm
3 62279 12 107500000 132349534 Loss Myeloproliferative neoplasm
4 70916 12 66000000 69800000 Loss Myeloproliferative neoplasm
5 71420 12 69800000 91200000 Loss Myeloproliferative neoplasm
6 75262 13 18400000 31100000 Loss Myeloproliferative neoplasm
7 75265 13 18400000 72100000 Loss Myeloproliferative neoplasm
8 92698 15 42700000 55800000 Loss Myeloproliferative neoplasm
9 93011 15 47498995 47525965 Loss FGF7 Myeloproliferative neoplasm
10 106738 17 1 11200000 Loss Myeloproliferative neoplasm
11 108733 17 22200000 28800000 Loss Myeloproliferative neoplasm
12 109394 17 25800000 31800000 Deletion NF1 Myeloproliferative neoplasm
13 114437 17 47600000 54900000 Loss Myeloproliferative neoplasm
14 115165 17 55117687 55118542 Loss CLTC Myeloproliferative neoplasm
15 124069 19 1 19800000 Loss Myeloproliferative neoplasm
16 126326 19 18251575 18251854 Loss JUND Myeloproliferative neoplasm
17 127984 19 38473374 38495178 Loss CEBPA Myeloproliferative neoplasm
18 142294 2 221300000 230700000 Loss Myeloproliferative neoplasm
19 147392 2 64000000 83700000 Loss Myeloproliferative neoplasm
20 150691 20 40134805 41251971 Copy number PTPRT Myeloproliferative neoplasm
21 150692 20 41976905 42131668 Copy number TOX2 Myeloproliferative neoplasm
22 151958 20 27100000 62435964 Loss Myeloproliferative neoplasm
23 151974 20 27500000 63025520 Deletion L3MBTL Myeloproliferative neoplasm
24 158649 21 35044781 35543405 Loss RUNX1 Myeloproliferative neoplasm
25 164350 22 36286416 36295356 Translate CEP1 Myeloproliferative neoplasm
26 164841 22 39916010 39959748 Gain L3MBTL2 Myeloproliferative neoplasm
27 166129 3 1 8700000 Loss Myeloproliferative neoplasm
28 170893 3 161200000 184200000 Loss Myeloproliferative neoplasm
29 177254 3 54400000 71800000 Loss Myeloproliferative neoplasm
30 179193 3 8700000 30800000 Gain Myeloproliferative neoplasm
31 192210 5 108662279 108714138 Gain PJA2 Myeloproliferative neoplasm
32 196632 5 17000000 76400000 Loss Myeloproliferative neoplasm
33 199864 5 44387421 44399741 Loss FGF10 Myeloproliferative neoplasm
34 227798 7 7200000 19500000 Loss Myeloproliferative neoplasm
35 230718 8 1 12700000 Loss Myeloproliferative neoplasm
36 233709 8 12700000 19100000 Loss Myeloproliferative neoplasm
37 241221 8 59800000 106100000 Loss Myeloproliferative neoplasm
38 244938 9 1 49000000 LOH JAK2 Myeloproliferative neoplasm
39 246129 9 116700000 129300000 Loss Myeloproliferative neoplasm

Expression for Myeloproliferative Neoplasm

Search GEO for disease gene expression data for Myeloproliferative Neoplasm.

Pathways for Myeloproliferative Neoplasm

Pathways related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.18 ABL1 BCR FGFR1 JAK2 KIT PDGFRA
2
Show member pathways
14.03 ABL1 CALR FGFR1 JAK2 KIT PDGFRA
3
Show member pathways
13.68 BCR CALR FGFR1 JAK2 KIT PDGFRA
4
Show member pathways
13.67 FGFR1 JAK2 KIT MPL PDGFRA PDGFRB
5
Show member pathways
13.5 ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB
6
Show member pathways
13.48 FGFR1 JAK2 KIT MPL PDGFRA PDGFRB
7
Show member pathways
13.4 FGFR1 JAK2 KIT PDGFRA PDGFRB STAT3
8
Show member pathways
13.33 FGFR1 JAK2 KIT PDGFRA PDGFRB PTPN11
9
Show member pathways
13.28 FGFR1 JAK2 KIT PDGFRA PDGFRB PTPN11
10
Show member pathways
13.05 FGFR1 JAK2 KIT PDGFRA PDGFRB STAT3
11
Show member pathways
12.96 FGFR1 JAK2 KIT PDGFRA PDGFRB
12
Show member pathways
12.91 JAK2 PDGFRA PDGFRB STAT3 STAT5B
13
Show member pathways
12.89 JAK2 MPL PTPN11 STAT3 STAT5B
14
Show member pathways
12.85 FGFR1 JAK2 PDGFRA PDGFRB STAT3
15
Show member pathways
12.75 FGFR1 JAK2 PDGFRA PDGFRB STAT3 STAT5B
16
Show member pathways
12.73 FGFR1 KIT PDGFRA PDGFRB PTPN11
17
Show member pathways
12.71 ABL1 FGFR1 KIT PDGFRA PDGFRB PTPN11
18
Show member pathways
12.56 JAK2 PDGFRA PDGFRB PTPN11 STAT3 STAT5B
19 12.55 JAK2 KIT MPL STAT3 STAT5B
20
Show member pathways
12.55 ABL1 BCR FGFR1 KIT PDGFRA PDGFRB
21 12.51 ABL1 PDGFRA PDGFRB STAT3
22
Show member pathways
12.51 JAK2 MPL PDGFRA PDGFRB PTPN11 STAT3
23
Show member pathways
12.47 JAK2 PTPN11 STAT3 STAT5B
24
Show member pathways
12.47 ABL1 PTPN11 STAT3 STAT5B
25 12.42 CALR PDGFRA PDGFRB STAT5B
26
Show member pathways
12.39 KIT PDGFRA PDGFRB PTPN11
27 12.33 ABL1 BCR FGFR1 JAK2 KIT PDGFRA
28
Show member pathways
12.26 JAK2 PTPN11 STAT3 STAT5B
29
Show member pathways
12.21 JAK2 PTPN11 STAT3 STAT5B
30
Show member pathways
12.17 BCR FGFR1 STAT3 STAT5B
31 12.17 ABL1 JAK2 PTPN11 STAT3 STAT5B
32
Show member pathways
12.15 JAK2 STAT3 STAT5B
33
Show member pathways
12.14 PDGFRA PDGFRB PTPN11 STAT3
34 12.11 JAK2 PTPN11 STAT3 STAT5B
35
Show member pathways
12.09 JAK2 KIT PTPN11 SH2B3 STAT3 STAT5B
36
Show member pathways
12.07 FGFR1 PDGFRA PDGFRB
37
Show member pathways
12.06 JAK2 PTPN11 STAT3 STAT5B
38 11.98 KIT MPL SH2B3
39
Show member pathways
11.95 JAK2 PTPN11 STAT5B
40 11.9 JAK2 STAT3 STAT5B
41 11.88 ABL1 JAK2 PTPN11 STAT3 STAT5B
42
Show member pathways
11.85 BCR FGFR1 STAT3 STAT5B
43 11.84 FGFR1 PDGFRA PDGFRB
44 11.83 JAK2 MPL PTPN11 STAT3 STAT5B
45
Show member pathways
11.82 JAK2 PTPN11 STAT3
46
Show member pathways
11.82 JAK2 PTPN11 SH2B3 STAT3 STAT5B
47
Show member pathways
11.81 FGFR1 KIT PDGFRB
48 11.76 JAK2 PTPN11 STAT3 STAT5B
49 11.72 JAK2 PTPN11 STAT3
50 11.69 JAK2 STAT3 STAT5B

GO Terms for Myeloproliferative Neoplasm

Cellular components related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 CALR KIT MPL PDGFRA PDGFRB
2 receptor complex GO:0043235 8.92 FGFR1 KIT PDGFRA PDGFRB

Biological processes related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 cell migration GO:0016477 9.98 FGFR1 JAK2 PDGFRA PDGFRB
2 positive regulation of cell migration GO:0030335 9.97 JAK2 KIT PDGFRA PDGFRB
3 MAPK cascade GO:0000165 9.97 FGFR1 JAK2 KIT PDGFRA PDGFRB
4 cytokine-mediated signaling pathway GO:0019221 9.97 JAK2 KIT MPL PTPN11 STAT3 STAT5B
5 positive regulation of MAPK cascade GO:0043410 9.94 FGFR1 KIT PDGFRA PDGFRB
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 ABL1 FGFR1 KIT PDGFRA PDGFRB PTPN11
7 negative regulation of signal transduction GO:0009968 9.92 FGFR1 KIT PDGFRA PDGFRB
8 positive regulation of cell proliferation GO:0008284 9.92 CALR FGFR1 JAK2 KIT PDGFRA PDGFRB
9 positive regulation of protein kinase B signaling GO:0051897 9.91 FGFR1 KIT PDGFRA PDGFRB PTPN11
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 ABL1 JAK2 KIT PDGFRA PDGFRB
11 cell chemotaxis GO:0060326 9.87 KIT PDGFRA PDGFRB
12 response to estradiol GO:0032355 9.87 CALR PDGFRB STAT3 STAT5B
13 positive regulation of kinase activity GO:0033674 9.86 FGFR1 KIT PDGFRA PDGFRB
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 JAK2 KIT STAT3
15 positive regulation of MAP kinase activity GO:0043406 9.83 FGFR1 KIT PDGFRB
16 regulation of cell adhesion GO:0030155 9.83 ABL1 JAK2 STAT5B
17 phosphatidylinositol-mediated signaling GO:0048015 9.83 FGFR1 PDGFRA PDGFRB
18 phosphatidylinositol phosphorylation GO:0046854 9.83 FGFR1 KIT PDGFRA PDGFRB PTPN11
19 positive regulation of mitotic cell cycle GO:0045931 9.79 ABL1 PTPN11 STAT5B
20 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.78 KIT PDGFRA PDGFRB
21 regulation of multicellular organism growth GO:0040014 9.77 PTPN11 STAT3 STAT5B
22 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 FGFR1 JAK2 KIT PDGFRA PDGFRB
23 JAK-STAT cascade GO:0007259 9.76 JAK2 STAT3 STAT5B
24 regulation of actin cytoskeleton reorganization GO:2000249 9.72 ABL1 PDGFRA
25 interleukin-6-mediated signaling pathway GO:0070102 9.72 JAK2 PTPN11 STAT3
26 cardiac myofibril assembly GO:0055003 9.71 PDGFRA PDGFRB
27 embryonic hemopoiesis GO:0035162 9.71 KIT SH2B3
28 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.71 JAK2 PDGFRB
29 megakaryocyte development GO:0035855 9.71 KIT PTPN11
30 negative regulation of cell-cell adhesion GO:0022408 9.71 ABL1 JAK2
31 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.71 JAK2 STAT3 STAT5B
32 interleukin-15-mediated signaling pathway GO:0035723 9.7 STAT3 STAT5B
33 interleukin-27-mediated signaling pathway GO:0070106 9.7 JAK2 STAT3
34 interleukin-35-mediated signaling pathway GO:0070757 9.7 JAK2 STAT3
35 protein autophosphorylation GO:0046777 9.7 ABL1 BCR FGFR1 JAK2 KIT PDGFRA
36 growth hormone receptor signaling pathway GO:0060396 9.69 JAK2 STAT3
37 interleukin-23-mediated signaling pathway GO:0038155 9.69 JAK2 STAT3
38 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.68 PDGFRA PDGFRB
39 Bergmann glial cell differentiation GO:0060020 9.68 ABL1 PTPN11
40 retina vasculature development in camera-type eye GO:0061298 9.67 PDGFRA PDGFRB
41 luteinization GO:0001553 9.66 PDGFRA STAT5B
42 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.65 ABL1 PDGFRB
43 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.63 PDGFRA PDGFRB
44 metanephric glomerular capillary formation GO:0072277 9.63 PDGFRA PDGFRB
45 positive regulation of growth factor dependent skeletal muscle satellite cell proliferation GO:1902728 9.59 JAK2 STAT3
46 positive regulation of phospholipase C activity GO:0010863 9.56 FGFR1 KIT PDGFRA PDGFRB
47 peptidyl-tyrosine phosphorylation GO:0018108 9.56 ABL1 BCR FGFR1 JAK2 KIT PDGFRA
48 platelet-derived growth factor receptor signaling pathway GO:0048008 9.1 ABL1 BCR JAK2 PDGFRA PDGFRB PTPN11
49 cell differentiation GO:0030154 10.18 ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB
50 negative regulation of apoptotic process GO:0043066 10.1 FGFR1 KIT PDGFRA PDGFRB STAT3 STAT5B

Molecular functions related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.91 ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB
2 kinase activity GO:0016301 9.91 ABL1 BCR FGFR1 JAK2 KIT PDGFRA
3 nucleotide binding GO:0000166 9.89 FGFR1 JAK2 KIT PDGFRA PDGFRB
4 transmembrane signaling receptor activity GO:0004888 9.85 FGFR1 KIT MPL PDGFRA PDGFRB
5 MAP kinase kinase kinase activity GO:0004709 9.71 FGFR1 KIT PDGFRA PDGFRB
6 growth factor binding GO:0019838 9.65 KIT PDGFRA PDGFRB
7 mitogen-activated protein kinase kinase binding GO:0031434 9.62 FGFR1 KIT PDGFRA PDGFRB
8 glucocorticoid receptor binding GO:0035259 9.58 STAT3 STAT5B
9 platelet-derived growth factor receptor binding GO:0005161 9.57 PDGFRA PDGFRB
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 FGFR1 KIT PDGFRA PDGFRB
11 insulin receptor substrate binding GO:0043560 9.55 JAK2 PTPN11
12 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.55 FGFR1 JAK2 KIT PDGFRA PDGFRB
13 platelet-derived growth factor binding GO:0048407 9.54 PDGFRA PDGFRB
14 peptide hormone receptor binding GO:0051428 9.52 JAK2 PTPN11
15 vascular endothelial growth factor binding GO:0038085 9.51 PDGFRA PDGFRB
16 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.35 FGFR1 KIT PDGFRA PDGFRB PTPN11
17 protein tyrosine kinase activity GO:0004713 9.23 ABL1 BCR FGFR1 JAK2 KIT PDGFRA
18 protein binding GO:0005515 10.46 ABL1 BCR CALR FGFR1 FIP1L1 JAK2
19 ATP binding GO:0005524 10.1 ABL1 BCR FGFR1 JAK2 KIT PDGFRA

Sources for Myeloproliferative Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....